Table 3.
Relationship of p-mTOR expression with clinicopathological characteristics in 218 TNBC patients
| Characteristis | Status | Positive for p-mTOR | Positive for Cyto p-mTOR | Positive for Nuclear or PN p-mTOR | |||
|---|---|---|---|---|---|---|---|
|
| |||||||
| No (%) | P value | No (%) | P value | No (%) | P value | ||
| Age | < 50 | 47 (44.8) | NS | 38 (36.2) | NS | 9 (8.6) | NS |
| ≥ 50 | 57 (50.4) | 45 (39.8) | 12 (10.6) | ||||
| Menopausal status | Pre-menopausal | 78 (45.3) | NS | 62 (36.0) | NS | 16 (9.3) | NS |
| Post-menopausal | 26 (56.5) | 21 (45.7) | 5 (10.9) | ||||
| Size | ≤ 2 | 27 (37.0) | 0.025 | 22 (30.1) | NS | 5 (6.8) | NS |
| > 2 | 77 (53.1) | 61 (42.1) | 16 (11.0) | ||||
| LNM | Present | 46 (58.2) | 0.019 | 32 (40.5) | NS | 14 (17.7) | 0.002 |
| Absent | 58 (41.7) | 51 (36.7) | 7 (5.0) | ||||
| Tumor grade | G2 | 36 (46.2) | NS | 28 (35.9) | NS | 8 (10.3) | NS |
| G3 | 58 (49.2) | 47 (39.8) | 11 (9.4) | ||||
| Tumor type | IC-NST | 94 (48.0) | NS | 75 (38.3) | NS | 19 (9.7) | NS |
| ILC | 1 (50.0) | 1 (50.0) | 0 (0) | ||||
| Other | 9 (45.0) | 7 (35.0) | 2 (10.0) | ||||
| Tumor embolus | Yes | 15 (62.5) | NS | 10 (41.7) | NS | 5 (20.8) | NS |
| No | 89 (45.9) | 73 (37.6) | 16 (8.3) | ||||
| Basal-like subtype | Yes | 63 (47.0) | NS | 50 (37.3) | NS | 13 (9.7) | NS |
| No | 41 (48.8) | 33 (39.3) | 8 (9.5) | ||||
| Clinical stage | 1 and 2 | 77 (43.5) | 0.010 | 63 (35.6) | NS | 14 (7.9) | NS |
| 3 | 27 (65.9) | 20 (48.8) | 7 (17.1) | ||||
| PIK3CA | Mutant | 18 (72.0) | 0.010 | 12 (48.0) | NS | 6 (24.0) | 0.020 |
| Wild-type | 86 (44.6) | 71 (36.8) | 15 (7.8) | ||||
Abbreviations: NS, not significant; IC-NST, invasive carcinoma of no special type; LNM, lymph nodes metastasis; ILC, invasive lobular carcinoma; Cyto, Cytoplasmic; PN, perinuclear.